Home care versus hospital care in patients with multiple myeloma treated with pamidronate

Int J Palliat Nurs. 2004 Mar;10(3):144-9. doi: 10.12968/ijpn.2004.10.3.12602.


Long-term bisphosphonate therapy has been shown to offer clinical benefit in the management of multiple myeloma. This study sought to explore the feasibility and potential advantages of monthly home-based intravenous infusions of pamidronate in patients with multiple myeloma. In a prospective crossover, multicentre trial, 37 patients were randomly allocated to receive 3 months of treatment with pamidronate given in the home followed by 3 months of treatment with pamidronate given in hospital or vice versa. Results from a patient preference questionnaire indicated most patients preferred treatment at home. Quality-of-life measurement was undertaken using the EORTC QLQ-C30 questionnaire. The results indicated a small, generally consistent, although not statistically significant, trend in favour of home care treatment. Extra nursing specialist time was required for home therapy. Home therapy with pamidronate in patients with multiple myeloma appeared feasible and safe and was preferred by patients in this study.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Attitude to Health*
  • Cross-Over Studies
  • Diphosphonates / adverse effects
  • Diphosphonates / therapeutic use*
  • Feasibility Studies
  • Female
  • Home Infusion Therapy / nursing
  • Home Infusion Therapy / psychology
  • Home Infusion Therapy / standards*
  • Hospitalization*
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / nursing
  • Multiple Myeloma* / psychology
  • Pamidronate
  • Program Evaluation
  • Prospective Studies
  • Quality of Life
  • Surveys and Questionnaires
  • Treatment Outcome
  • United Kingdom


  • Antineoplastic Agents
  • Diphosphonates
  • Pamidronate